<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/219377-new-phenylamidine-derivatives-processes-for-their-preparation-and-their-use-as-pharmaceuticals by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 11:55:04 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 219377:&quot;NEW PHENYLAMIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS&quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot;NEW PHENYLAMIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS&quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The invention relates to new phenylamidine derivatives, processes for preparing them and their use as pharmaceutical compositions. The phenylamidines; according to the invention correspond to the general formula I</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>New phenylamidine derivatives, processes for<br>
preparing them and their use as pharmaceutical<br>
compositions<br>
The invention relates to new phenylamidine derivatives,<br>
processes for preparing them and their use in<br>
pharmaceutical compositions. The phenylamidines<br>
according to the invention correspond to the general<br>
formula I<br>
(Formula  Removed)<br>
wherein<br>
A denotes X1-CmH2m-X2-, in which m is an integer 2, 3,<br>
4, 5 or 6<br>
or<br>
and<br>
j denotes O, NH or NCH3 ;<br>
X2 denotes 0, NH, NCH3 or<br>
- 2 -<br>
X3 denotes -Xi-CnH2n- in which n is an integer 1 or 2;<br>
X4 denotes -Cn-Han-Xj.-, wherein n is an integer 1 or 2;<br>
R! denotes Cs.7-cycloalkyl, Arl7 OArlf CH2-Ar2;<br>
CR4R5Ar3, or C(CH3)2R6;<br><br>
R2 denotes H, Cx.6-alkyl; OH, halogen, or<br>
O-fCj.g)-alkyl;<br>
R3 denotes H, or C^.g-alkyl;<br>
R4 denotes C^-alkyl, CF3, CH2OH, COOH, or<br>
COO(C^4) -alkyl;<br>
R5 denotes H, Cx-4-alkyl, or CF3 and<br>
R4 and R5 may also together form a C4_6-alkylene group;<br>
R6 denotes CH2OH, COOH, COO (C^) alkyl, CONR9R10, or<br>
CH2NR9R10;<br>
R7 denotes H, halogen, OH, C^.g-alkyl or C^g<br>
R8 denotes H, halogen, OH, C^.g-alkyl or C-L.g<br>
R9 denotes H, Ci-g-alkyl, phenyl, phenyl- (C^<br>
CORllf COORllf CHO, CONH2/ CONHRu, S02-(C^g-<br>
S02-phenyl, wherein the phenyl ring may be mono- or<br>
polysubstituted by halogen, CF3, C1.4-alkyl, OH, or<br>
C1_4-alkoxy;<br>
R10 denotes H or C-L.g-alkyl and<br>
R9 and R10 together may represent a C4.6-alkylene group;<br>
RH denotes Ci.g-alkyl, C5.7-cycloalkyl, aryl,<br>
heteroaryl, aralkyl or heteroaryl- (C^gwherein<br>
the aryl or heteroaryl groups may be monoor<br>
polysubstituted by Cl, F, CF3, C^-alkyl, OH or<br>
C^-alkoxy;<br>
denotes an optionally mono- or polysubstituted aryl<br>
group, with the exception of an unsubstituted<br>
phenyl group or a phenyl group which is<br>
monosubstituted by halogen, C-^-alkyl or<br>
C1_4-alkoxy;<br>
Ar2 denotes an optionally mono- or polysubstituted aryl<br>
group, with the exception of an unsubstituted<br>
phenyl group;<br>
Ar3 denotes an optionally mono- or polysubstituted aryl<br>
group<br>
with the proviso that<br>
R cannot represent an unsubstituted phenyl group<br>
bound via a C^-alkylene unit;<br>
optionally in the form of individual optical isomers,<br>
mixtures of the individual enantiomers, or racemates and<br>
in the form of the free bases or the corresponding acid<br>
addition salts with pharmacologically acceptable acids.<br>
Preferred compounds according to general formula I are<br>
those wherein<br>
A denotes X1-Cm-H2m-X2 in which m is an integer 2<br>
and<br>
is 0;<br>
X2 is<br>
X3 denotes -X.i-CnK2n- _ wherein n is an integer 1 or 2 ;<br>
X4 denotes -CnE2li-X.i- wherein n is an integer 1 or 2 ;<br>
R! denotes C5_7-cycloalkyl , Arl7 OArx, CH2-Ar2;<br>
CR4R5Ar3/ or C(CH3)2R6;<br>
R2 denotes H, C^g-alky!, OH, Cl , or 0- (C^) -alkyl ;<br>
R3 denotes H, or C^.g-alkyl;<br>
R4 denotes C1.4-alkyl, CF3, or CH2OH;<br>
R5 denotes H, C1.4-alkyl, CF3, or CH2OH and<br>
R4 and R5 together may also form a C4_6-alkylene group;<br>
R6 denotes CH2OH, COOH, COO (C^) alkyl, CONR9R10/ or<br>
CH2NR9R10;<br>
R7 denotes H, F, Cl , Br, OH, CVg-alkyI or C1_6-<br>
R8 denotes H, F, Cl, Br, OH, C^.g-alkyl or C1_6-alkoxy;<br>
R9 denotes H, or Cg-alkyl;<br>
R10 denotes H or C-g-alkyl and<br>
R9 and R10 together may also represent a C4_6-alkylene<br>
group ;<br>
Art denotes an optionally mono- or polysubstituted aryl<br>
group, other than an unsubstituted phenyl group or a<br>
phenyl group which is monosubstituted by halogen,<br>
Ci-4-alkyl or C1_4-alkoxy;<br>
Ar2 denotes an optionally mono- or polysubstituted aryl<br>
group, with the exception of an unsubstituted phenyl<br>
group;<br>
Ar3 denotes an optionally mono- or polysubstituted aryl<br>
group<br>
with the proviso that<br>
R! cannot represent an unsubstituted phenyl group<br>
bound via a C1.4-alkylene unit;<br>
optionally in the form of the individual optical<br>
isomers, mixtures of the individual enantiomers or<br>
racemates and in the form of the free bases or the<br>
corresponding acid addition salts with pharmacologically<br>
acceptable acids.<br>
Particularly preferred compounds of general formula I<br>
are those wherein<br>
and<br>
Xj is 0;<br>
X3 denotes X1-CH2;<br>
X4 denotes CE2-'K1;<br>
R! denotes C5.7-cycloalkyl , Arlf OArlf CH2-Ar2;<br>
CR4R5Ar3/ or C(CH3 ) 2R6 ;<br>
R2 denotes H, OH, or 0- (C^g) -alkyl ;<br>
fR3 denotes H;<br>
R4 denotes CH3, or CH2OH;<br>
R5 denotes H, CH3, or CH2OH and<br>
R4 and R5 together may also denote a C4.6-alkylene group;<br>
R6 denotes CH2OH, COOH, COO (C^) -alkyl , CONR9R10, or<br>
CH2NR9R10;<br>
R7 denotes H;<br>
R8 denotes H;<br>
R9 denotes H, or C^g-alkyl;<br>
R10 denotes H or C^.g-alkyl and<br>
R9 and R10 together may also denote a C4.6-alkylene group;<br>
-L denotes an aryl group optionally mono- or<br>
polysubstituted by hydroxy or by hydroxy and<br>
Ar2 denotes an aryl group optionally mono- or<br>
polysubstituted by hydroxy or by hydroxy and<br>
Cj _6 -alkyl;<br>
Ar3 denotes an aryl group optionally mono- or<br>
polysubstituted by hydroxy or by hydroxy and<br>
optionally in the form of the individual optical<br>
isomers, mixtures of the individual enantiomers or<br>
racemates and in the form of the free bases or the<br>
corresponding acid addition salts with pharmacologically<br>
acceptable acids.<br>
Unless specifically stated otherwise, the general<br>
definitions are used as follows:<br>
C^-Alkyl, Ci.g-alkyl and C-^g-alkyl, respectively,<br>
generally denote branched or unbranched hydrocarbon<br>
groups having 1 to 4, 6 or 8 carbon atoms respectively.<br>
These may optionally be substituted by one or more<br>
halogen atoms, preferably fluorine, which may be the<br>
same or different from one another. The following<br>
hydrocarbon groups are mentioned by way of example:<br>
methyl, ethyl, propyl, 1-methylethyl (isopropyl) , nbutyl,<br>
1-methylpropyl, 2-methylpropyl, 1,1-<br>
dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl , 3-<br>
methylbutyl, 1, 1-dimethylpropyl, 1, 2-dimethylpropyl ,<br>
2 , 2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-<br>
methylpentyl, 2-methylphenyl, 3-methylpentyl, 4-<br>
methylpentyl, 1, 1-dimethylbutyl, 1, 2-dimethylbutyl, 1,3-<br>
dimethylbutyl, 2 , 2-dimethylbutyl, 2 , 3-dimethylbutyl ,<br>
3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-<br>
trimethylpropyl, 1, 2, 2-trimethylpropyl, 1-ethyl-lmethylpropyl<br>
and 1- ethyl -2-methylpropyl . Unless<br>
otherwise specified, lower alkyl groups having 1 to 4<br>
carbon atoms such as methyl, ethyl, propyl, isopropyl,<br>
n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-<br>
dimethylethyl are preferred.<br>
Aryl generally denotes an aromatic group having 6 to 10<br>
carbon atoms, the aromatic group may also be substituted<br>
by one or more lower alkyl groups, trifluoromethyl<br>
groups, cyano groups, alkoxy groups, nitro groups, amino<br>
groups and/or one or more halogen atoms - which may be<br>
identical or different; the preferred aryl group is an<br>
optionally substituted phenyl group, the preferred<br>
substituents being halogen (such as fluorine, chlorine<br>
or bromine) and hydroxyl.<br>
Aralkyl generally denotes a C7.14-aryl group bound via an<br>
alkylene chain, in which the aromatic group may be<br>
substituted by one or more lower alkyl groups, alkoxy<br>
groups, nitro groups, amino groups and/or one or more<br>
halogen atoms, which may be identical or different.<br>
Aralkyl groups having 1 to 6 carbon atoms in the<br>
aliphatic part and 6 carbon atoms in the aromatic part<br>
are preferred.<br>
Unless otherwise stated, the preferred aralkyl groups<br>
are benzyl, phenethyl and phenylpropyl or 2-phenylisopropyl.<br>
Alkoxy generally represents a straight-chained or<br>
branched Cl.e-hydrocarbon group bound via an oxygen atom.<br>
A lower alkoxy group having 1 to 3 carbon atoms is<br>
preferred. The methoxy group is particularly preferred.<br>
Unless otherwise stated, amino denotes an NH2 function<br>
which may optionally be substituted by one or two<br>
Ci.e-alkyl, aryl or aralkyl groups, which may be<br>
identical or different.<br>
Alkylamino represents, by way of example, methylamino,<br>
ethylamino, propylamino, 1-methylene-ethylamino,<br>
butylamino, 1-methylpropylamino, 2-methylpropylamino or<br>
1, l-dimethylethylamino.<br>
Dialkylamino denotes, for example, dimethylamino,<br>
diethylamino, dipropylamino, dibutylamino, di-(1-<br>
methylethyl)amino, di-(1-methylpropyl)amino, di - 2 -<br>
methylpropylamino, ethylmethylamino or<br>
methylpropylamino.<br>
Cycloalkyl generally denotes a saturated or unsaturated<br>
cyclic hydrocarbon group having 5 to 9 carbon atoms<br>
which may optionally be substituted by a halogen atom or<br>
a number of halogen atoms, preferably fluorine, which<br>
may be the same or different. Cyclic hydrocarbon groups<br>
having 3 to 6 carbon atoms are preferred. Examples<br>
include cyclopropyl, cyclobutyl, cyclopentyl,<br>
cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl,<br>
cycloheptenyl, cycloheptadienyl, cyclooctyl,<br>
cyclooctenyl, cyclooctadienyl and cyclononinyl.<br>
Heteroaryl, within the scope of the above definition,<br>
generally represents a 5- to 6-membered ring which may<br>
contain oxygen, sulphur and/or nitrogen as heteroatoms<br>
and onto which another aromatic ring may be fused. 5-<br>
and 6-membered aromatic rings which contain an oxygen, a<br>
sulphur and/or up to two nitrogen atoms and which are<br>
optionally benzocondensed are preferred.<br>
Examples of particular heterocyclic systems include:<br>
acridinyl, acridonyl, alkylpyridinyl, anthraquinonyl,<br>
ascorbyl, azaazulenyl, azabenzanthracenyl,<br>
azabenzanthrenyl, azachrysenyl, azacyclazinyl,<br>
azaindolyl, azanaphthacenyl, azanaphthalenyl, azaprenyl,<br>
azatriphenylenyl, azepinyl, azinoindolyl, azinopyrrolyl,<br>
benzacridinyl, benzazapinyl, benzofuryl,<br>
benzonaphthyridinyl, benzopyranonyl, benzopyranyl,<br>
benzopyronyl, benzoquinolinyl, benzoquinolizinyl,<br>
benzothiepinyl, benzothiophenyl, benzylisoquinolinyl,<br>
bipyridinyl, butyrolactonyl, caprolactamyl, carbazolyl,<br>
carbolinyl, catechinyl, chromenopyronyl,<br>
chromonopyranyl, cumarinyl, cumaronyl,<br>
decahydroquinolinyl, decahydroquinolonyl,<br>
diazaanthracenyl, diazaphenanthrenyl, dibenzazapinyl,<br>
dibenzofuranyl, dibenzothiophenyl, dichromylenyl,<br>
dihydrofuranyl, dihydroisocumarinyl,<br>
dihydroisoquinolinyl, dihydropyranyl, dihydropyridinyl,<br>
dihydropyridonyl, dihy^dropyronyl, dihydrothiopyranyl,<br>
diprylenyl, dioxanthylenyl, oenantholactamyl, flavanyl,<br>
flavonyl, fluoranyl, fluoresceinyl, furandionyl,<br>
furanochromanyl, furanonyl, furanoquinolinyl, furanyl,<br>
furopyranyl, furopyronyl, heteroazulenyl,<br>
hexahydropyrazinoisoquinolinyl, hydrofuranyl,<br>
hydrofuranonyl, hydroindolyl, hydropyranyl,<br>
hydropyridinyl, hydropyrrolyl, hydroquinolinyl,<br>
hydrothiochromenyl, hydrothiophenyl, indolizidinyl,<br>
indolizinyl, indolonyl, isatinyl, isatogenyl,<br>
isobenzofurandionyl, isobenzfuranyl, isochromanyl,<br>
isoflavonyl, isoindolinyl, isoindolobenzazapinyl,<br>
isoindolyl, isoquinolinyl, isoquinuclidinyl, lactamyl,<br>
lactonyl, maleimidyl, monoazabenzonaphthenyl,<br>
naphthalenyl, naphthimidazopyridindionyl,<br>
naphthindolizinedionyl, naphthodihydropyranyl,<br>
naphthofuranyl, naphthyridinyl, oxepinyl, oxindolyl,<br>
oxolenyl, perhydroazolopyridinyl, perhydroindolyl,<br>
phenanthracquinonyl, phthalideisoquinolinyl,<br>
phthalimidyl, phthalonyl, piperidinyl, piperidonyl,<br>
prolinyl, parazinyl, pyranoazinyl, pyranoazolyl,<br>
pyranopyrandionyl, pyranopyridinyl, pyranoquinolinyl,<br>
pyranopyrazinyl, pyranyl, pyrazolopyridinyl,<br>
pyridinethionyl, pyridinonaphthalenyl,<br>
pyridinopyridinyl, pyridinyl, pyridocolinyl,<br>
pyridoindolyl, pyridopyridinyl, pyridopyrimidinyl,<br>
pyridopyrrolyl, pyridoquinolinyl, pyronyl, pyrrocolinyl,<br>
pyrrolidinyl, pyrrolizidinyl, pyrrolizinyl,<br>
pyrrolodioazinyl, pyrrolonyl, pyrrolopyrimidyl,<br>
pyrroloquinolonyl, pyrrolyl, quinacridonyl, quinolinyl,<br>
quinolizidinyl, quinolizinyl, quinolonyl, quinuclidinyl,<br>
rhodaminyl, spirocumaranyl, succinimidyl, sulpholanyl,<br>
sulpholenyl, tetrahydrofuranyl, tetrahydroisoquinolinyl,<br>
tetrahydropyranyl, tetrahydropyridinyl,<br>
tetrahydrothiapyranyl, tetrahydrothiophenyl,<br>
tetrahydrothipyranonyl, tetrahydrothipyranyl, tetronyl,<br>
thiaphenyl, thiachromanyl, thiadecalinyl,<br>
thianaphthenyl, thiapyranyl, thiapyronyl,<br>
thiazolopyridinyl, thienopyridinyl, thienopyrrolyl,<br>
thienothiophenyl, thiepinyl, thiochromenyl,<br>
thiocumarinyl, thiopyranyl, triazaanthracenyl,<br>
triazinoindolyl, triazolopyridinyl, tropanyl, xanthenyl,<br>
xanthonyl, xanthydrolyl, adeninyl, alloxanyl,<br>
alloxazinyl, anthranilyl, azabenzanthrenyl,<br>
azabenzonaphthenyl, azanaphthacenyl, azaphenoxazinyl,<br>
azapurinyl, azinyl, azoloazinyl, azolyl, barbituric<br>
acid, benzazinyl, benzimidazolethionyl,<br>
benzimidazolonyl, benzisothiazolyl, benzisoxazolyl,<br>
benzocinnolinyl, benzodiazocinyl, benzodioxolanyl,<br>
benzodioxolyl, benzopyridazinyl, benzothiazepinyl,<br>
benzothiazinyl, benzothiazolyl, benzoxazinyl,<br>
benzoxazolinonyl, benzoxazolyl, cinnolinyl, depsidinyl,<br>
diazaphenanthrenyl, diazepinyl, diazinyl,<br>
dibenzoxazepinyl, dihydrobenzimidazolyl,<br>
dihydrobenzothiazinyl, dihydrooxazolyl,<br>
dihydropyridazinyl, dihydropyrimidinyl,<br>
dihydrothiazinyl, dioxanyl, dioxenyl, dioxepinyl,<br>
dioxinonyl, dioxolanyl, dioxolonyl, dioxopiperazinyl,<br>
dipyrimidopyrazinyl, dithiolanyl, dithiolenyl,<br>
dithiolyl, flavinyl, furopyrimidinyl, glycocyamidinyl,<br>
guaninyl, hexahydropyrazinoisoquinolinyl,<br>
hexahydropyridazinyl, hydantoinyl, hydroimidazolyl,<br>
hydroparazinyl, hydropyrazolyl, hydropyridazinyl,<br>
hydropyrimidinyl, imidazolinyl, imidazolyl,<br>
imidazoquinazolinyl, imidazothiazolyl,<br>
indazolebenzopyrazolyl, indoxazenyl, inosinyl,<br>
isoalloxazinyl, isothiazolyl, isoxazolidinyl,<br>
isoxazolinonyl, isoxazolinyl, isoxazolonyl, isoxazolyl,<br>
lumazinyl, methylthyminyl, methyluracilyl, morpholinyl,<br>
naphthimidazolyl, oroticyl, oxathianyl, oxathiolanyl,<br>
oxazinonyl, oxazolidinonyl, oxazolidinyl, oxazolidonyl,<br>
oxazolinonyl, oxazolinyl, oxazolonyl,<br>
oxazolopyrimidinyl, oxazolyl, perhydrocinnolinyl,<br>
perhydropyrroloazinyl, perhydropyrrolothiazinyl,<br>
perhydrothiazinonyl, perimidinyl, phenazinyl,<br>
phenothiazinyl, phenoxathiinyl, phenoxazinyl,<br>
phenoxazonyl, phthalazinyl, piperazindionyl,<br>
piperazinodionyl, polyquinoxalinyl, pteridinyl,<br>
pterinyl, purinyl, pyrazinyl, pyrazolidinyl,<br>
pyrazolidonyl, pyrazolinonyl, parazolinyl,<br>
pyrazolobenzodiazepinyl, pyrazolonyl,<br>
pyrazolopyrimidinyl, pyrazolotriazinyl, pyrazolyl,<br>
pyridazinyl, pyridazonyl, pyridopyrazinyl,<br>
pyridopyrimidinyl, pyrimidinethionyl, pyrimidinyl,<br>
pyrimidioriyl, pyrimidoazepinyl, pyrimidopteridinyl,<br>
pyrrolobenzodiazepinyl, pyrrolodiazinyl,<br>
pyrrolopyrimidinyl, quinazolidinyl, quinazolinonyl,<br>
quinazolinyl, quinoxalinyl, sultamyl, sultinyl,<br>
sultonyl, tetrahydrooxazolyl, tetrahydropyrazinyl,<br>
tetrahydropyridazinyl, tetrahydroquinoxalinyl,<br>
tetrahydrothiazolyl, thiazepinyl, thiazinyl,<br>
thiazolidinonyl, thiazolidinyl, thiazolinonyl,<br>
thiazolinyl, thiazolobenzimidazolyl, thiazolyl,<br>
thienopyrimidinyl, thiazolidinonyl, thyminyl,<br>
triazolopyrimidinyl, uracilyl, xanthinyl, xylitolyl,<br>
azabenzonaphththenyl, benzofuroxanyl, benzothiadiazinyl,<br>
benzotriazepinonyl, benzotriazolyl, benzoxadiazinyl,<br>
dioxadiazinyl, dithiadazolyl, dithiazolyl, furazanyl,<br>
furoxanyl, hydrotriazolyl, hydroxytrizinyl, oxadiazinyl,<br>
oxadiazolyl, oxathiazinonyl, oxatriazolyl, pentazinyl,<br>
pentazolyl, petrazinyl, polyoxadiazolyl, sydonyl,<br>
tetraoxanyl, tetrazepinyl, tetrazinyl, tetrazolyl,<br>
thiadiazinyl, thiadiazolinyl, thiadiazolyl,<br>
thiadioxazinyl, thiatriazinyl, thiatriazolyl,<br>
thiatriazolyl, triazepinyl, triazinoindolyl, triazinyl,<br>
triazolinedionyl, triazolinyl, triazolyl, trioxanyl,<br>
triphenodioxazinyl, triphenodithiazinyl,<br>
trithiadiazepinyl, trithianyl or trioxolanyl.<br>
Particularly preferred heteroaryl groups include, for<br>
example, thienyl, furyl, pyridyl, pyrimidyl, pyrazinyl,<br>
pyridazinyl, quinolyl,, isoquinolyl, quinazolyl,<br>
quinoxalyl, thiazolyl, benzothiazolyl, isothiazolyl,<br>
.oxazolyl, benzoxazolyl, isoxazolyl, imidazolyl,<br>
benzimidazolyl, pyrazolyl and indolyl.<br>
The new compounds may be prepared by a variety of<br>
methods, which comprise a further feature of the<br>
invention. The following procedures may be used to<br>
prepare compounds of the invention:<br>
1) Imidoesters of formula II<br>
(Figure Removed)<br>
 (wherein Rx to R4, A and B are as hereinbefore<br>
defined and -OR or -SR denote the residue of an<br>
alcohol or thiol preferably in which R denotes a<br>
Ci.g-alkyl or benzyl group) may be reacted with<br>
ammonia.<br>
The reaction is conveniently carried out in an<br>
organic solvent at temperatures between about 0°C<br>
and the boiling temperature of the reaction<br>
mixture, preferably between ambient temperature and<br>
about 100°C or boiling temperature, if this is<br>
lower. Suitable solvents are polar solvents such<br>
as methanol, ethanol and propanol.<br>
If the starting materials are sufficiently acidstable,<br>
the reaction may be carried out via the<br>
corresponding acid imide chlorides instead of the<br>
imido esters.<br>
2) In order to prepare compounds of formula I wherein<br>
A is linked via 0 or S to at least one of the ring<br>
systems:<br>
(a) a phenol or thiophenol of formula III<br>
wherein Z denotes OH or SH and R17 R2 and R3 are as<br>
hereinbefore defined, is reacted with a compound of<br>
general formula IV<br>
[IV)<br>
wherein A is as hereinbefore defined and L denotes<br>
a nucleofugic leaving group, or<br>
(b) a phenol or thiophenol of formula V<br>
 (Figure Removed)<br>
wherein Z is as hereinbefore defined, is reacted<br>
with a compound of formula VI:<br>
(Figure Removed)<br>
wherein A, Rt, R2, R3 and L are as hereinbefore<br>
defined.<br>
The reaction is carried out in aprotic solvents<br>
such as dimethylsulphoxide, dimethylformamide,<br>
acetonitrile or alcohols such as methanol, ethanol<br>
or propanol using a base (metal carbonate, metal<br>
hydroxide, metal hydride) at temperatures between<br>
about 0 and 140°C or the boiling temperature of the<br>
reaction mixture.<br>
The phenols or thiophenols may also be used in the<br>
form of salts, e.g. the alkali metal salts. The<br>
nucleofugic leaving group may be, for example, a<br>
halogen such as Br or Cl.<br>
3) An amidoxime of formula VII<br>
NOH<br>
(VII)<br>
wherein A and Rt to R3 are as hereinbefore defined,<br>
is reduced.<br>
Catalytic hydrogenation, particularly with Raney nickel<br>
in a lower alcohol such as methanol, is preferred as a<br>
method for reducing the amidoxime.<br>
Appropriately, the amidoxime of the formula (VII) is<br>
dissolved in methanol with the addition of the<br>
calculated quantity of the particular acid the salt of<br>
which is desired as an end product, and hydrogenated at<br>
ambient temperature under slight pressure, e.g. 5 bar,<br>
until the uptake of hydrogen has ceased.<br>
The starting materials may be obtained from known<br>
compounds by conventional methods.<br>
Thus, the starting materials for process 1) may be<br>
obtained from the corresponding nitriles by reacting<br>
with HCl via the step of the imide chlorides or directly<br>
by reacting with C^g-alcohols or benzyl alcohol, for<br>
example, in the presence of an acid such as HCl.<br>
Reacting the nitriles with H2S in solvents such as<br>
pyridine or dimethylformamide in the presence of a base<br>
such as triethylamine with subsequent alkylation or<br>
benzylation also results in compounds of formula II.<br>
Starting from carboxylic acid amides, which moreover<br>
correspond to the compounds of formula II by reacting<br>
with a trialkyloxonium salt such as triethyloxoniumtetrafluoroborate<br>
in a solvent such as dichloromethane,<br>
tetrahydrofuran or dioxane at temperatures of between 0<br>
and 50°C, preferably at ambient temperature, compounds<br>
of formula II are obtained.<br>
In order to prepare the starting materials of general<br>
formula VII, the corresponding amidoximes may be reacted<br>
instead of amidines in a process analogous to process 1)<br>
or 2), or by analogous reaction of corresponding<br>
nitriles, from which the starting materials of general<br>
formula VII are finally obtained by the addition of<br>
hydroxylamine.<br>
It has been found that the compounds of formula I are<br>
characterised by their versatility in therapeutic<br>
applications. Particular mention should be made of<br>
those applications in which the LTB4-receptorantagonistic<br>
properties play a part. These include, in<br>
particular, arthritis, asthma, chronic obstructive lung<br>
diseases, e.g. chronic bronchitis, psoriasis, ulcerative<br>
colitis, gastro- or enteropathy induced by non-steroidal<br>
antiphlogistics, cystic fibrosis, Alzheimer's disease,<br>
shock, reperfusion damage/ischaemia, atherosclerosis and<br>
multiple sclerosis.<br>
The new compounds may also be used to treat illnesses or<br>
conditions in which the passage of cells from the blood<br>
through the vascular endothelium into the tissue is of<br>
importance (e.g. metastasis) or diseases and conditions<br>
in which the combination of LTB4 or another molecule<br>
(such as 12-HETE) with the LTB4-receptor affects cell<br>
proliferation (such as chronic myeloid leukaemia).<br>
The new compounds may be used in conjunction with other<br>
active substances, e.g. those used for the same<br>
indications, or with antiallergics, secretolytics, (32-<br>
adrenergics, steroids administered by inhalation,<br>
antihistamines and/or PAF-antagonists. They may be<br>
administered topically, orally, transdermally, nasally,<br>
parenterally or by inhalation.<br>
The activities may be investigated pharmacologically and<br>
biochemically using tests such as those described in<br>
WO 93/16036, pages 15 to 17, which are thus incorporated<br>
herein by reference.<br>
The therapeutic or prophylactic dose is dependent not<br>
only on the potency of the individual compounds and the<br>
body weight of the patient but also on the nature and<br>
gravity of the condition being treated. For oral use<br>
the dose is between 10 and 500 mg, preferably between 20<br>
and 250 mg. For administration by inhalation, the dose<br>
given to the patient is between about 0.5 and 25,<br>
preferably between about 2 and 20 mg of active<br>
substance.<br>
Solutions for inhalation generally contain between about<br>
0.5 and 5% of active substance. The new compounds may<br>
be administered in conventional preparations, e.g. as<br>
tablets, coated tablets, capsules, lozenges, powders,<br>
granules, solutions, emulsions, syrups, aerosols for<br>
inhalation, ointments and suppositories.<br>
The Examples which follow show some possible<br>
formulations for the preparations:<br>
Examples of formulations<br>
1. Tablets<br>
Composition:<br>
Active substance according to the<br>
invention 20 parts by weight<br>
Stearic acid 6 parts by weight<br>
Glucose 474 parts by weight<br>
The ingredients are processed in the usual way to form<br>
tablets weighing 500 mg. If desired, the content of<br>
active substance may be increased or reduced and the<br>
quantity of glucose reduced or increased accordingly.<br>
2. Suppositories<br>
Composition:<br>
Active substance according to the<br>
invention 1000 parts by weight<br>
Powdered lactose 45 parts by weight<br>
Cocoa butter 1555 parts by weight<br>
The ingredients are processed in the usual way to form<br>
suppositories weighing 1.7 g.<br>
3. Powders for inhalation<br>
Micronised powdered active substance (compound of<br>
formula I; particle size approximately 0.5 to 7 /xm) are<br>
packed into hard gelatine capsules in a quantity of<br>
5 mg, optionally with the addition of micronised<br>
lactose. The powder is inhaled from conventional<br>
inhalers, e.g. according to DE-A 33 45 722, to which<br>
reference is hereby made.<br>
(Figure Removed)<br><br>
Example of synthesis<br>
Amidoxime: X = para-C(=NOH)NH2<br>
2.0 g of the nitrile of the above formula (X = para-CN)<br>
are placed in 40 ml of ethanol, refluxed and a mixture<br>
of 1 g of Na2C03 in 5 ml of water and 1.24 g of<br>
hydroxylamine x HCl is added dropwise. After 5 hours'<br>
refluxing the solvent is distilled off, the residue is<br>
stirred with 50 ml of water, extracted 3 x with 50 ml of<br>
ethyl acetate and the combined organic phases are dried.<br>
After filtering, the substance is evaporated down in<br>
vacuo and the residue is purified by flash<br>
chromatography (silica gel 60, CH2Cl2/methanol 9:1). The<br>
product is dissolved in ethanol, acidified with<br>
ethanolic HCl and precipitated as the hydrochloride<br>
using ether. The oil obtained is crystallised with<br>
ethyl acetate. Yield: 2.0 g of white crystals.<br>
4-[[3-[[4-[1-(4-Hydroxyphenyl)-1-methylethyl]phenoxy]-<br>
methyl]phenyl]methoxy]benzolcarboximidamide<br>
hydrochloride (X = para-C(=NH)-NH2)<br>
2.0 g of the amidoxime of the above formula (X = para-<br>
C(=NOH)~NH2) are dissolved in 50 ml of methanol and<br>
hydrogenated with 5 g of methanol-moistened Raney nickel<br>
with the addition of 1 ml of 20% ammonium chloride<br>
solution for 5 hours under normal pressure and at<br>
ambient temperature. The nickel is suction filtered and<br>
the solution is filtered through kieselguhr. After<br>
concentration by evaporation in vacuo, the residue is<br>
stirred with 50 ml of water. The crystals are suction<br>
filtered and recrystallised twice from ethanol/ether.<br>
Yield: 1.0 g of the amidine compound (the above formula,<br>
X = para-C(=NH)-NH2 as hydrochloride, m.p. 234-236°C.<br>
The following compounds are also obtained, inter alia,<br>
using this procedure:<br>
(Table Removed)<br>
Surprisingly, the compounds in the Example and in the<br>
Table have outstanding Kt values which are largely within<br>
the range from 0.2 to 0.7 nmol/1 (RB.LTB4/U937 cells).<br><br><br><br>
Claims<br>
1. Compounds of general formula I<br>
NH,<br>
(Formula  Removed)<br>
wherein<br>
A denotes X1-CmH2m-X2/ in which m is an integer 2, 3,<br>
4, 5 or 6<br>
or<br>
and<br>
x denotes 0, NH or NCH3;<br>
X2 denotes 0, NH, NCH3 or<br>
X3 denotes ~Xi-CnU2n- in which n is an integer 1 or 2 ;<br>
X4 denotes -Cn-H^-X!-, wherein n is an integer 1 or 2;<br>
R! denotes C5.7-cycloalkyl, Arl r OArl7 CH2-Ar2;<br>
CR4R5Ar3, or C(CH3 ) 2R6 ;<br>
R2 denotes H, C^g-alkyl, OH, halogen, or O- ( C alkyl;<br>
R3 denotes H, or C^g-<br>
R4 denotes C^-alkyl, CF3, CH2OH, COOH, or<br>
000(0!. 4) -alkyl;<br>
R5 denotes H, C1_4-alkyl, or CF3 and<br>
^,1<br>
R4 and R5 may also together form a C4_6-alkylene group;<br>
R6 denotes CH2OH, COOH, COO (C^ ) -alkyl, CONR9R10, or<br>
CH2NR9R10;<br>
R7 denotes H, halogen, OH, C-^g-alkyl or C^.g-alkoxy;<br>
Re denotes H, halogen, OH, C-^g-alkyl or C^g-<br>
R9 denotes H, C^g-alkyl, phenyl, phenyl- (C-^g-<br>
CORu, COOR11; CHO, CONH2 , CONHRllf SO2- (C^g-<br>
SO2 -phenyl, wherein the phenyl ring may be mono- or<br>
polysubstituted by halogen, CF3, C1.4-alkyl/ OH,<br>
C1.4-alkoxy;<br>
R10 denotes H or C^.g-alkyl and<br>
R9 and R10 together may represent a C4.6-alkylene group;<br>
denotes Ci.g-alkyl, C5.7-cycloalkyl, aryl,<br>
heteroaryl, aralkyl or heteroaryl- (Ci^gwherein<br>
the aryl or heteroaryl groups may be monoor<br>
polysubstituted by Cl, F, CF3, Cx^-alkyl, OH or<br>
C1_4-alkoxy;<br>
denotes an optionally mono- or polysubstituted aryl<br>
group, with the exception of an unsubstituted<br>
phenyl group or a phenyl group which is<br>
monosubstituted by halogen, C1.4-alkyl or<br>
Ar2 denotes an optionally mono- or polysubstituted aryl<br>
group, with the exception of an unsubstituted<br>
phenyl group;<br>
Ar3 denotes an optionally mono- or polysubstituted aryl<br>
group<br>
,t<br>
with the proviso that<br>
R! cannot represent an unsubstituted phenyl group<br>
bound via a C1_4-alkylene unit;<br>
optionally in the form of individual optical isomers,<br>
mixtures of individual enantiomers, or racemates and in<br>
the form of the free bases or the corresponding acid<br>
addition salts with pharmacologically acceptable acids.<br>
2. Compounds according to general formula I wherein<br>
A denotes X1-Cm-H2m-X2 in which m is the integer 2<br>
and<br>
Xj_ is O;<br>
X2 is<br>
X3 denotes X^Cy^ wherein n is the integer 1 or 2;<br>
X4 denotes C^n'^i wherein n is the integer 1 or 2;<br>
R! denotes C5.7-cycloalkyl, Arlf OAr^ CH2-Ar2;<br>
CR4R5Ar3, C(CH3)2R6;<br>
R2 denotes H, Ci.g-alkyi, OH, Cl, O- (d.6) -alkyl ;<br>
R3 denotes H, Ci. 6- alkyl;<br>
R4 denotes C^-alkyl, CF3/ CH2OH;<br>
R5 denotes H, C^-alkyl, CF3, CH2OH and<br>
R4 and R5 together may also form a C4_6-alkylene group;<br>
R6 denotes CH2OH, COOH, COO (^.4) alkyl, CONR9R10,<br>
CH2NR9R10;<br>
R7 denotes H, F, Cl, Br, OH, C^g-alkyl or C1_6-alkoxy;<br>
R8 denotes H, F, Cl, Br, OH, C^g-alkyl or C1_6-alkoxy;<br>
R9 denotes H, Ci.g-alkyl;<br>
R10 denotes H or Ci.g-alkyl and<br>
R9 and R10 together may also represent a C4_6-alkylene<br>
group ;<br>
x denotes an optionally mono- or polysubstituted aryl<br>
group, with the exception of the unsubstituted phenyl<br>
group and the phenyl group which is monosubstituted by<br>
halogen, C^-alkyl and monosubstituted by C1.4-alkoxy;<br>
Ar2 denotes an optionally mono- or polysubstituted<br>
aryl group, with the exception of the unsubstituted<br>
phenyl group ;<br>
Ar3 denotes an optionally mono- or polysubstituted aryl<br>
group<br>
with the proviso that<br>
R! cannot represent an unsubstituted phenyl group<br>
bound via a C1_4-alkylene unit;<br>
optionally in the form of individual optical isomers,<br>
mixtures of individual enantiomers or racemates and /• in<br>
the form of the free bases or the corresponding acid<br>
addition salts with pharmacologically acceptable acids.<br>
3. Compounds according to general formula I wherein<br>
A denotes<br>
and<br>
Xj. is O;<br>
X3 denotes X1-CE2;<br>
X4 denotes<br>
Rx denotes C5.7-cycloalkyl, Arl7 OAr^ CH2-Ar2;<br>
CR4R5Ar3, C(CH3)2R6;<br>
R2 denotes H, OH, 0- (C^g) -alkyl ;<br>
R3 denotes H;<br>
R4 denotes CH3, CH2OH;<br>
R5 denotes H, CH3 , CH2OH and<br>
R4 and R5 together may also denote a C4_6-alkylene group;<br>
R6 denotes CH2OH, COOH, COO (C^) -alkyl , CONR9R10/<br>
R7 denotes H;<br>
R8 denotes H;<br>
R9 denotes H, Ci.g-<br>
R10 denotes H or C^.g-alkyl and<br>
R9 and R10 together may also denote a C4_6-alkylene group;<br>
x denotes an aryl group optionally mono- or<br>
polysubstituted by hydroxy or by hydroxy and<br>
Ar2 denotes an aryl group optionally mono- or<br>
polysubstituted by hydroxy or by hydroxy and<br>
Ar3 denotes an aryl group optionally mono- or<br>
polysubstituted by hydroxy or by hydroxy and<br>
optionally in the form of individual optical isomers,<br>
mixtures of individual enantiomers or racemates and in<br>
the form of the free bases or the corresponding acid<br>
addition salts with pharmacologically acceptable acids.<br>
4 . A process for preparing compounds according to<br>
general formula I, as claimed in claim 1, which<br>
comprises either a) reacting an imido ester of general<br>
formula II<br>
(Formula  Removed)<br>
wherein Rx to R4 and A are defined as in claim 1 and -OR<br>
represents the residue of an alcohol with ammonia.<br>
or b) where it is desired to form a compound in which A<br>
is linked to at least one of the ring systems via 0 or<br>
S, either<br>
(i) reacting a phenol or thiophenol of formula III<br>
(Formual Removed)<br>
wherein Z denotes OH or SH and R1; R2 and R3 are as<br>
defined in claim 1, with a compound of general formula<br>
IV<br>
(Formula  Removed)<br>
wherein A is defined as in claim 1 and L denotes a<br>
nucleofugic leaving group;<br>
or ii) reacting a phenol or thiophenol of general<br>
formula V<br>
(Figure Removed)<br>
wherein z is defined as in (i) above with a compound of<br>
formula VT<br>
(Formula Removed)<br>
wherein A, R17 Rj, R3 and L are defined as in claim 1;<br>
or c) reducing an amidoxime of general formula (Formula  Removed)<br><br>
wherein A and Rt to R3 are defined as in claim 1;<br>
followed where necessary or desired, by separation of<br>
any mixture of optical isomers into individual isomers,<br>
and formation of any acid-addition salt or free base<br>
from the free base or acid-addition salt respectively-<br>
5. A process according to part a) of claim 4, wherein<br>
the reaction takes place in a polar organic solvent, at<br>
(Figure Removed)<br>
a temperature between about 0*C and the boiling '<br>
temperature of the reaction mixture. I '<br>
S. A process as claimed in claim 5 wherein the<br>
reaction is carried out in methanol, ethanol orlpropanol<br>
at between ambient temperature and about 10()"C or the<br>
boiling temperature of the;reaction mixture, if I this is<br>
lower<br>
7. A process according to part b)(i) or b}(iij of<br>
claim 4, wherein the reaction is carried out in^an<br>
aprotic solvent in the presence of a base. i<br>
8. A process as claimed in claim 7 wherein the<br>
reaction is carried out in dimethylsulphoxide,<br>
dimethylformamide, acetonitrile or a lower alkahol, and<br>
the base is a metal carbonate, metal hydroxide p:r metal<br>
hydride. i<br>
9. A process according to any of claims 4 b), 7 or 8,<br>
which is carried out at a. tempeirature b«=&gt;t-.weaii Qi ,ind<br>
140°C or between, 0"C and the boiling temperature of the<br>
reaction mixture if this is lower. :<br>
10. A process according to any of claims 4 b) or 7 to<br>
9, wherein the phenols or thiophenols axe used in the<br>
form of their alkali metal salts, and where necessary or<br>
desired, a halogen is used as the nucleofugic leaving<br>
group. XI. A process according to part c) of claim 4/; wherein<br>
the reduction is carried out in the presence of a Raney<br>
nickel catalyst in a lower alkanol solvent, under ah<br>
elevated pressure of approximately 5 bar. <br><br>
12. A process according to claim 4 a) or claim 5 in<br>
which, instead of an imidq ester of general formula II,<br>
a corresponding acid imide chloride is used as starting<br>
material. <br>
13. Pharmaceutical preparation which comprises a<br>
compound according to any one of claims X to 3 or an<br>
acid addition salt thereof together with a<br>
pharmaceutically acceptable carrier, excipient or<br>
diluent.<br>
14. Use of a compound according to any one of claims 1<br>
to 3 in a pharmaceutical composition.<br>
15. Use of compounds according to claim 14 as a<br>
pharmaceutical having LTB4-antagonistic activity.<br>
16. Use of a. compound of gene,ral formula. I ap claimed<br>
in claim 1, their stereoisomers and the acid addition<br>
salts thereof for preparing.a drug for the therapeutic<br>
treatment of arthritis, asthma, chronic obstructive lung<br>
disease such as chronic bronchitis, psoriasis?/<br>
ulcerative colitis, gastropathy or enteropathy induced<br>
by non-steroidal antiphlogistics, cystic fibrosis,.<br>
Alzheimer's disease, shock,:reperfusion<br>
damage/ischaemia, atherosclerosis and multiple<br>
sclerosis.<br>
17. A method of treating- a condition requiring<br>
LTB4-antagonistic activity which comprises administering<br>
to a subject an effective amount: of a compound oi:<br>
formula (I) as claimed in claim 1 or a stereoisomer or<br>
acid-addition salt thereof.<br>
18. Compounds of general formula I substantially as hereinbefore<br>
described with reference to the foregoing examples.<br>
19. A process for preparing compounds substantially as<br>
hereinbefore described with reference to the foregoing examples.<br>
20. Pharmaceutical preparation substantially as herein described<br>
with reference to the foregoing examples.<br><br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1ERUwtMTk5Ni1BYnN0cmFjdC0wNC0wMy0yMDA4LnBkZg==" target="_blank" style="word-wrap:break-word;">2669-DEL-1996-Abstract-04-03-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1hYnN0cmFjdC0yNC0wNC0yMDA4LnBkZg==" target="_blank" style="word-wrap:break-word;">2669-del-1996-abstract-24-04-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">2669-del-1996-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1ERUwtMTk5Ni1DbGFpbXMtMDQtMDMtMjAwOC5wZGY=" target="_blank" style="word-wrap:break-word;">2669-DEL-1996-Claims-04-03-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1jbGFpbXMtMjQtMDQtMjAwOC5wZGY=" target="_blank" style="word-wrap:break-word;">2669-del-1996-claims-24-04-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">2669-del-1996-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1ERUwtMTk5Ni1Db3JyZXNwb25kZW5jZS1PdGhlcnMtMDQtMDMtMjAwOC5wZGY=" target="_blank" style="word-wrap:break-word;">2669-DEL-1996-Correspondence-Others-04-03-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1jb3JyZXNwb25kZW5jZS1vdGhlcnMtMTUtMDQtMjAwOC5wZGY=" target="_blank" style="word-wrap:break-word;">2669-del-1996-correspondence-others-15-04-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1jb3JyZXNwb25kZW5jZS1vdGhlcnMtMjQtMDQtMjAwOC5wZGY=" target="_blank" style="word-wrap:break-word;">2669-del-1996-correspondence-others-24-04-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1jb3JyZXNwb25kZW5jZS1vdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">2669-del-1996-correspondence-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1jb3JyZXNwb25kZW5jZS1wby5wZGY=" target="_blank" style="word-wrap:break-word;">2669-del-1996-correspondence-po.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1ERUwtMTk5Ni1EZXNjcmlwdGlvbiAoQ29tcGxldGUpLTA0LTAzLTIwMDgucGRm" target="_blank" style="word-wrap:break-word;">2669-DEL-1996-Description (Complete)-04-03-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1kZXNjcmlwdGlvbiAoY29tcGxldGUpLTI0LTA0LTIwMDgucGRm" target="_blank" style="word-wrap:break-word;">2669-del-1996-description (complete)-24-04-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1kZXNjcmlwdGlvbiAoY29tcGxldGUpLnBkZg==" target="_blank" style="word-wrap:break-word;">2669-del-1996-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1mb3JtLTEtMjQtMDQtMjAwOC5wZGY=" target="_blank" style="word-wrap:break-word;">2669-del-1996-form-1-24-04-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1mb3JtLTEucGRm" target="_blank" style="word-wrap:break-word;">2669-del-1996-form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1mb3JtLTE4LnBkZg==" target="_blank" style="word-wrap:break-word;">2669-del-1996-form-18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1mb3JtLTItMjQtMDQtMjAwOC5wZGY=" target="_blank" style="word-wrap:break-word;">2669-del-1996-form-2-24-04-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1mb3JtLTIucGRm" target="_blank" style="word-wrap:break-word;">2669-del-1996-form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1mb3JtLTMucGRm" target="_blank" style="word-wrap:break-word;">2669-del-1996-form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1mb3JtLTQucGRm" target="_blank" style="word-wrap:break-word;">2669-del-1996-form-4.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1mb3JtLTUucGRm" target="_blank" style="word-wrap:break-word;">2669-del-1996-form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1mb3JtLTYucGRm" target="_blank" style="word-wrap:break-word;">2669-del-1996-form-6.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1ERUwtMTk5Ni1HUEEtMDQtMDMtMjAwOC5wZGY=" target="_blank" style="word-wrap:break-word;">2669-DEL-1996-GPA-04-03-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1kZWwtMTk5Ni1ncGEucGRm" target="_blank" style="word-wrap:break-word;">2669-del-1996-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1ERUwtMTk5Ni1PdGhlciBEb2N1bWVudC0wNC0wMy0yMDA4LnBkZg==" target="_blank" style="word-wrap:break-word;">2669-DEL-1996-Other Document-04-03-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1ERUwtMTk5Ni1QZXRpdGlvbi0xMzctMDQtMDMtMjAwOC5wZGY=" target="_blank" style="word-wrap:break-word;">2669-DEL-1996-Petition-137-04-03-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjY2OS1ERUwtMTk5Ni1QZXRpdGlvbi0xMzgtMDQtMDMtMjAwOC5wZGY=" target="_blank" style="word-wrap:break-word;">2669-DEL-1996-Petition-138-04-03-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QuanBn" target="_blank" style="word-wrap:break-word;">abstract.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="219373-a-spraying-device.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="219378-an-isolated-nucleic-acid-that-encodes-the-protein-tcdb2-useful-to-express-a-potentiator-for-insectidical-tcda1.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>219377</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>2669/DEL/1996</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>25/2008</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>20-Jun-2008</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>30-Apr-2008</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>02-Dec-1996</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>BOEHRINGER INGELHEIM KG.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td></td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>ANDREAS DING</td>
											<td></td>
										</tr>
										<tr>
											<td>2</td>
											<td>FRANZ BIRKE</td>
											<td></td>
										</tr>
										<tr>
											<td>3</td>
											<td>HANS JENNWEIN</td>
											<td></td>
										</tr>
										<tr>
											<td>4</td>
											<td>ERNST-OTTO RENTH</td>
											<td></td>
										</tr>
										<tr>
											<td>5</td>
											<td>CHRISTOPHER MEADE</td>
											<td></td>
										</tr>
										<tr>
											<td>6</td>
											<td>KURT SCHROMM</td>
											<td></td>
										</tr>
										<tr>
											<td>7</td>
											<td>RALF ANDERSKEWITZ</td>
											<td></td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07C 257/18</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>N/A</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td></td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>195 46 452.4</td>
									<td>1995-12-13</td>
								    <td>Germany</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/219377-new-phenylamidine-derivatives-processes-for-their-preparation-and-their-use-as-pharmaceuticals by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 11:55:05 GMT -->
</html>
